Psoriasis and oncology: is there a way out?

In severe psoriasis, systemic therapy is required, but the number of studies on the use of biologics drugs in patients with existing or history of cancer is limited, which creates difficulties in prescribing this group of drugs. The presented clinical case demonstrates the interdisciplinary interaction between a dermatologist and an oncologic surgeon. A patient diagnosed with psoriasis, psoriatic arthritis, and basal cell carcinoma underwent successful therapy with the IL-23 inhibitor risankizumab, which has demonstrated high safety and efficacy in the treatment of psoriasis, and surgical removal of the basal cell carcinoma by Mohs micrographic surgery. For patients with psoriasis and an existing or history of cancer, multidisciplinary collaboration is required to determine optimal therapeutic tactics.

1. Kruglova L. S., Bakulev L. A., Korotaeva T. V., et al., “Psoriasis” 2022. (In Russ.).

2. Nast A., Smith C., Spuls P. I. et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris – part 2: specific clinical and comorbid situations // J Eur Acad Dermatol Venereol. 2021. Vol. 35. № 2. P. 281–317.

3. Vaengebjerg S., Skov L., Egeberg A. et al. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis // JAMA Dermatol. 2020. Vol. 56. № 4. P. 421–429.

4. Griffin L. L., Ali F. R., Lear J. T. Non-melanoma skin cancer // Clin Med (Lond). 2016. Vol. 16. № 1. P. 62–65.

5. https://gco.iarc.fr/today/data/factsheets/cancers/17-Non-melanoma-skin-cancer-fact-sheet.pdf

6. https://www.wcrf.org/cancer-trends/skin-cancer-statistics/

7. https://www.cancer.net/cancer-types/skin-cancer-non-melanoma/statistics

8. Menter A., Strober B.E., Kaplan D. H. et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics // J Am Acad Dermatol. 2019. Vol. 80. № 4. P. 1029–1072.

9. Nast A., Smith C., Spuls P. I. et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations // J Eur Acad Dermatol Venereol. 2020. Vol. 34. № 11. P. 2461–2498.

10. Holroyd C., Seth R. et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis – Executive summary // Rheumatology (Oxford). 2019. Vol. 58. № 2. P. 220–226.

11. Wang X., Liu Q., Wu L. et al. Risk of non-melanoma skin cancer in patients with psoriasis: An updated evidence from systematic review with meta-analysis // J Cancer. 2020. Vol. 11. № 5. P. 1047–1055.

12. Gordon K. B., Lebwohl M., Papp K. A. et al. Long-term safety of Risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis // Br J Dermatol. 2022. Vol. 186. № 3. P. 466–475.

13. Gordon K. B., Blauvelt A., Coates L. et al. Risankizumab long-term safety in patients with psoriatic disease: integrated analyses of data from psoriasis and psoriatic arthritis clinical trials. Poster presented at: 2022 European Academy of Dermatology and Venerology (EADV) Virtual Congress; September 7–10, 2022. Poster 1607.

14. Reich K., Gooderham M., Thaçi D. et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial // Lancet. 2019. Vol. 394. P. 576–586.

15. Warren R. B., Blauvelt A., Poulin Y. et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy–assessor-blinded clinical trial // British Journal of Dermatology. 2019.

16. Clinical guidelines of the Ministry of Health of the Russian Federation «Basal cell skin cancer». 2020. (In Russ.).

17. NCCN Clinical Practice Guidelines in Oncology Basal Cell Skin Cancer (version 1.2024).

18. Connolly S. M., Baker D. R., Coldiron B. M. et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: A report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery // J Am Acad Dermatol. 2012. Vol. 67. № 4. P. 531–550.